Takatsuka Shinya, Morita Takahiro, Horikiri Yuji, Yamahara Hiroshi, Saji Hideo
Pharmaceutical Technology Department, CMC Research Laboratories, Tanabe Seiyaku Co. Ltd., 3-16-89 Kashima, Yodogawa-ku, Osaka 532-8505, Japan.
Int J Pharm. 2008 Feb 12;349(1-2):94-100. doi: 10.1016/j.ijpharm.2007.07.031. Epub 2007 Aug 1.
The absorption enhancing effects of various combinations of a mucolytic agent and a non-ionic surfactant on the intestinal absorption of poorly absorbed hydrophilic compounds were examined. Fluorescein isothiocyanate-labeled dextran with an average molecular weight of ca. 4.4 kDa (FD-4) was used as a model compound. Cysteine derivatives such as N-acetylcysteine (NAC), S-carboxymethylcysteine (SCMC), S-ethylcysteine (SEC), and S-methylcysteine (SMC) were selected as mucolytic agents. A homogeneous series of single chain polyoxyethylene alkyl ethers were employed as non-ionic surfactants. Various dosing solutions were administered into rat jejunum, and the bioavailability of FD-4 was determined. Unlike NAC, the agents such as SCMC, SEC, and SMC, which do not possess a free thiol group, did not show any apparent enhancement of intestinal FD-4 absorption, when they were co-administered with p-t-octyl phenol polyoxyethylene-9.5 (Triton X-100, TX-100). In addition, the absorption enhancement was dependent on the kinds of polyoxyethylene alkyl ethers used, when used in combination with NAC. For a constant alkyl chain of 12 with a varying polyoxyethylene (POE) chain length, the surfactant with a short to medium POE chain length such as lauryl poly (4.2) oxyethylene ether (BL-4.2) and lauryl poly (9) oxyethylene ether (BL-9) were effective. In addition, for a constant alkyl chain of 18 with a varying POE chain length, the surfactants with a longer POE chain length such as oleyl poly (15) oxyethylene ether (BO-15) and stearyl poly (20) oxyethylene ether (BS-20) showed the effective enhancement. All these results suggest that a mucolytic agent not possessing a free thiol group is not effective for enhancing the intestinal absorption of poorly absorbed hydrophilic compounds. Also, they indicate that the combination of a mucolytic agent possessing a free thiol group and a non-ionic surfactant either with a short to medium POE chain length and a medium alkyl chain length, or with a longer POE chain length and a longer alkyl chain length shows the effective enhancement. This fundamental information might be useful for finding the optimal combination.
研究了黏液溶解剂与非离子表面活性剂的各种组合对吸收较差的亲水性化合物肠道吸收的促进作用。使用平均分子量约为4.4 kDa的异硫氰酸荧光素标记的葡聚糖(FD-4)作为模型化合物。选择半胱氨酸衍生物如N-乙酰半胱氨酸(NAC)、S-羧甲基半胱氨酸(SCMC)、S-乙基半胱氨酸(SEC)和S-甲基半胱氨酸(SMC)作为黏液溶解剂。采用一系列均一的单链聚氧乙烯烷基醚作为非离子表面活性剂。将各种给药溶液注入大鼠空肠,并测定FD-4的生物利用度。与NAC不同,不具有游离巯基的SCMC、SEC和SMC等药剂与对叔辛基苯酚聚氧乙烯-9.5(吐温X-100,TX-100)共同给药时,未显示出对肠道FD-4吸收有任何明显增强作用。此外,与NAC联合使用时,吸收增强作用取决于所用聚氧乙烯烷基醚的种类。对于具有12个碳原子的恒定烷基链且聚氧乙烯(POE)链长度不同的情况,具有短至中等POE链长度的表面活性剂如十二烷基聚(4.2)氧乙烯醚(BL-4.2)和十二烷基聚(9)氧乙烯醚(BL-9)是有效的。此外,对于具有18个碳原子的恒定烷基链且POE链长度不同的情况,具有较长POE链长度的表面活性剂如油基聚(15)氧乙烯醚(BO-15)和硬脂基聚(20)氧乙烯醚(BS-20)显示出有效的增强作用。所有这些结果表明,不具有游离巯基的黏液溶解剂对增强吸收较差的亲水性化合物的肠道吸收无效。此外,它们表明,具有游离巯基的黏液溶解剂与具有短至中等POE链长度和中等烷基链长度或具有较长POE链长度和较长烷基链长度的非离子表面活性剂的组合显示出有效的增强作用。这一基础信息可能有助于找到最佳组合。